Dual CD40/CD28 co-stimulation reprograms the solid-tumor microenvironment to unleash CAR-T and endogenous anti-tumor immunity
Chimeric antigen receptor (CAR) T-cell therapy has shown limited efficacy against solid tumors, owing to poor T-cell persistence, an immunosuppressive tumor microenvironment (TME) and cancer immune evasion. Here we describe LACO-Stim (lymphocytes-APC co-stimulator), a chimeric co-stimulatory molecule composed of an agonistic anti-CD40 single-chain variable fragment (scFv) and the CD28…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
